癌症免疫疗法的更新
The Renewal of Cancer Immunotherapy.
作者信息
Bulgarelli Jenny, Pignatta Sara, Petrini Massimiliano, Ridolfi Laura
机构信息
Immunotherapy, Cell Therapy and Biobank Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
出版信息
Vaccines (Basel). 2023 Mar 4;11(3):592. doi: 10.3390/vaccines11030592.
Abstract
Cancer immunotherapy embraces many current, promising therapeutic approaches to eradicate tumors by activating host antitumor activity [...].
摘要
癌症免疫疗法包含许多当前有前景的治疗方法，即通过激活宿主抗肿瘤活性来根除肿瘤[……]。
相似文献
1
The Renewal of Cancer Immunotherapy.癌症免疫疗法的更新
Vaccines (Basel). 2023 Mar 4;11(3):592. doi: 10.3390/vaccines11030592.
2
Alloantigen-activated (AAA) CD4 T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice.同种异体抗原激活的（AAA）CD4 T 细胞可重新激活宿主内源性 T 细胞免疫，以消除小鼠体内已建立的肿瘤。
J Exp Clin Cancer Res. 2021 Oct 8;40(1):314. doi: 10.1186/s13046-021-02102-6.
3
Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting.癌症免疫治疗中的纳米疫苗：聚焦于树突状细胞靶向
Int Immunopharmacol. 2022 Dec;113(Pt B):109434. doi: 10.1016/j.intimp.2022.109434. Epub 2022 Nov 16.
4
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy.靶向核苷酸代谢：增强癌症免疫治疗的有前途的方法。
J Hematol Oncol. 2022 Apr 27;15(1):45. doi: 10.1186/s13045-022-01263-x.
5
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.癌症起始细胞的免疫调节和免疫抗性特性：对免疫治疗临床成功的意义。
Immunol Invest. 2017 Apr;46(3):221-238. doi: 10.1080/08820139.2017.1280051. Epub 2017 Mar 13.
6
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.5,6-二甲基呫吨酮-4-乙酸联合B7.1（CD80）介导的免疫疗法进行血管攻击可克服免疫抵抗，并导致大肿瘤和多个肿瘤病灶的根除。
Cancer Res. 2001 Mar 1;61(5):1948-56.
7
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.聚合物 PD-L1 封锁纳米颗粒用于癌症光热免疫治疗。
Biomaterials. 2022 Jan;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 6.
8
Multifunctional STING-Activating Mn O @Au-dsDNA/DOX Nanoparticle for Antitumor Immunotherapy.用于抗肿瘤免疫治疗的多功能STING激活型MnO@Au-dsDNA/DOX纳米颗粒
Adv Healthc Mater. 2020 Jul;9(13):e2000064. doi: 10.1002/adhm.202000064. Epub 2020 Jun 2.
9
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.用抗癌药物增强基于自然杀伤细胞的免疫疗法：一个视角。
Trends Mol Med. 2017 Dec;23(12):1156-1175. doi: 10.1016/j.molmed.2017.10.002. Epub 2017 Nov 10.
10
Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies.基于树突状细胞的免疫疗法——一种治疗内分泌恶性肿瘤的有前景的治疗方法。
Horm Metab Res. 2008 Feb;40(2):89-98. doi: 10.1055/s-2007-1022549.
引用本文的文献
1
Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy.抗 PD-1/PD-L1 免疫治疗中晚期肺癌患者的糖基标志物。
Acta Biochim Biophys Sin (Shanghai). 2024 Jun 28;56(8):1099-1107. doi: 10.3724/abbs.2024110.
本文引用的文献
1
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.肿瘤浸润淋巴细胞治疗或伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233.
2
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.自体肿瘤裂解物负载树突状细胞疫苗接种与新诊断和复发性胶质母细胞瘤患者生存延长的相关性：一项 3 期前瞻性外部对照队列试验。
JAMA Oncol. 2023 Jan 1;9(1):112-121. doi: 10.1001/jamaoncol.2022.5370.
3
Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy.瞄准目标：在联合免疫疗法中重新启用癌症疫苗
Vaccines (Basel). 2021 May 15;9(5):509. doi: 10.3390/vaccines9050509.
4
Circulating biomarkers predictive of tumor response to cancer immunotherapy.循环生物标志物预测癌症免疫治疗的肿瘤反应。
Expert Rev Mol Diagn. 2019 Oct;19(10):895-904. doi: 10.1080/14737159.2019.1659728. Epub 2019 Sep 10.
5
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.T 细胞功能障碍和耗竭的特征可预测癌症免疫疗法的反应。
Nat Med. 2018 Oct;24(10):1550-1558. doi: 10.1038/s41591-018-0136-1. Epub 2018 Aug 20.
6
Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma.工程化嵌合抗原受体T细胞用于治疗胶质母细胞瘤。
J Target Ther Cancer. 2017 Aug;6(4):22-25.
7
Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.嵌合抗原受体 T 细胞在非霍奇金淋巴瘤中的新作用。
J Natl Compr Canc Netw. 2017 Nov;15(11):1429-1437. doi: 10.6004/jnccn.2017.7045.
8
Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.嵌合抗原受体 T 细胞的癌症免疫疗法：从研究工作台到装配线。
Biotechnol J. 2018 Feb;13(2). doi: 10.1002/biot.201700097. Epub 2017 Oct 30.
9
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
10
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.纳武利尤单抗与伊匹木单抗联合治疗对比伊匹木单抗单药治疗未经治疗的黑色素瘤
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
Zotero 插件